John Liddicoat
Cited by
Cited by
Precision medicine: drowning in a regulatory soup?
D Nicol, T Bubela, D Chalmers, J Charbonneau, C Critchley, J Dickinson, ...
Journal of Law and the Biosciences 3 (2), 281-303, 2016
Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic
D Nicol, L Eckstein, M Morrison, JS Sherkow, M Otlowski, T Whitton, ...
Genome medicine 9, 1-4, 2017
Myriad's impact on gene patents
M Aboy, K Liddell, J Liddicoat, C Crespo
Nature biotechnology 34 (11), 1119-1123, 2016
International divergence in gene patenting
D Nicol, RC Dreyfuss, ER Gold, W Li, J Liddicoat, G Van Overwalle
Annual review of genomics and human genetics 20, 519-541, 2019
How does emerging patent case law in the US and Europe affect precision medicine?
M Aboy, K Liddell, C Crespo, IG Cohen, J Liddicoat, S Gerke, T Minssen
Nature biotechnology 37 (10), 1118-1125, 2019
After Myriad, what makes a gene patent claim 'markedly different' from nature?
M Aboy, J Liddicoat, K Liddell, M Jordan, C Crespo
Nature biotechnology 35 (9), 820-825, 2017
The examination effect: A comparison of the outcome of patent examination in the US, Europe and Australia
AF Christie, C Dent, J Liddicoat
J. Marshall Rev. Intell. Prop. L. 16, i, 2016
Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?
M Aboy, C Crespo, K Liddell, J Liddicoat, M Jordan
Nature Biotechnology 36 (12), 1146-1149, 2018
Mayo’s impact on patent applications related to biotechnology, diagnostics and personalized medicine
M Aboy, C Crespo, K Liddell, T Minssen, J Liddicoat
Nature Biotechnology 37 (5), 513-518, 2019
A role for virtual biotechnology companies in drug discovery and development?
D Nicol, J Liddicoat, C Critchley
Three dimensions of patent infringement: Liability for creation and distribution of CAD files
J Liddicoat, JL Nielsen, D Nicol
Australian Intellectual Property Journal, 2016
Are the gene-patent storm clouds dissipating? A global snapshot
J Liddicoat, T Whitton, D Nicol
Nature Biotechnology 33 (4), 347-352, 2015
Continental drift? Do European clinical genetic testing laboratories have a patent problem?
J Liddicoat, K Liddell, AH McCarthy, S Hogarth, M Aboy, D Nicol, S Patton, ...
European Journal of Human Genetics 27 (7), 997-1007, 2019
The Effects of Myriad and Mayo on Molecular-Test Development in the United States and Europe: Interviews from the Frontline
J Liddicoat, K Liddell, M Aboy
Vand. J. Ent. & Tech. L. 22, 785, 2019
Provenance and risk in transfer of biological materials
J Nielsen, T Bubela, DRC Chalmers, A Johns, L Kahl, J Kamens, ...
PLoS Biology 16 (8), e2006031, 2018
The innovation pool in biotechnology: the role of patents in facilitating innovation
D Nicol, JL Nielsen, J Liddicoat, C Critchley, T Whitton
Available at SSRN 2503314, 2014
Do patents impede the provision of genetic tests in Australia?
D Nicol, J Liddicoat
Australian Health Review 37 (3), 281-285, 2013
Mapping the European patent landscape for medical uses of known products
M Aboy, K Liddell, J Liddicoat, C Crespo, M Jordan
Nature Biotechnology 39 (11), 1336-1343, 2021
Has the EU incentive for drug repositioning been effective? An empirical analysis of the “+ 1” regulatory exclusivity
J Liddicoat, K Liddell, M Aboy, J Wested
IIC-International Review of Intellectual Property and Competition Law 52 …, 2021
The multiple dimensions of intellectual property infringement in the 3D printing era
JL Nielsen, J Liddicoat
The system can't perform the operation now. Try again later.
Articles 1–20